Pfizer Inc (PFE)

$27.65 +0.55 (2.03%)
Market Cap 154.08B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.39
Forward PE 9.12
Profit Margin 12.42%
Debt to Equity Ratio 0.66
Volume 41,879,600
Avg Vol 48,193,785
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 85%
Beta 0.47
Analysts Sell
Price Target $28.58

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Fliptax
Fliptax Feb. 28 at 3:51 PM
$PFE lets get back to $60+
0 · Reply
Fliptax
Fliptax Feb. 28 at 3:51 PM
$PFE
0 · Reply
TradyMcGradyy
TradyMcGradyy Feb. 28 at 10:36 AM
$BNTX $MRNA $NVAX $PFE
0 · Reply
RolandBless
RolandBless Feb. 28 at 10:10 AM
$PFE pharmaceutical portfolio stability in focus
0 · Reply
SatoshiTrades
SatoshiTrades Feb. 27 at 11:39 PM
$ENSC in PLAY. Ensysce launches formal strategic review — partnerships, licensing, or full buyout on the table. Abuse-deterrent TAAP™ + MPAR® = prime Big Pharma target. $PFE makes strategic sense. Small cap. M&A catalyst. Massive upside potential.
1 · Reply
JBS_84
JBS_84 Feb. 27 at 11:20 PM
$PFE Brilliant let's buy calls that are already expired.
1 · Reply
DragonAlgo
DragonAlgo Feb. 27 at 10:02 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-02-27 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.62 Stop: $0.45 TP1: $0.81 TP2: $1.05 TP3: $1.49 🔗 https://dragonalgo.com
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 27 at 8:50 PM
$PFE wtf is this last hour of trading, it’s literally low volume algo walk up trading
1 · Reply
JBS_84
JBS_84 Feb. 27 at 8:15 PM
$PFE should close in the 27.40s
1 · Reply
SeriouslyWhy
SeriouslyWhy Feb. 27 at 8:06 PM
$PFE your welcome everyone just needed me to leave
2 · Reply
Latest News on PFE
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 1 day ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

Feb 26, 2026, 7:48 AM EST - 2 days ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 3 days ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 4 days ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 4 days ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 4 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 5 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 7 days ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 9 days ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 9 days ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 10 days ago

Pfizer: The Rebound Looks Unsustainable

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 11 days ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 15 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 16 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 6:08 PM EST - 16 days ago

Pfizer: A Great Opportunity Post Earnings

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 16 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 17 days ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 17 days ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 8, 2026, 10:19 PM EST - 19 days ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 21 days ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

Feb 6, 2026, 7:25 AM EST - 22 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 22 days ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 22 days ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 24 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 24 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 24 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 24 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:56 AM EST - 24 days ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 24 days ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 25 days ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 25 days ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 25 days ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 25 days ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 25 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 25 days ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Feb 3, 2026, 7:02 AM EST - 25 days ago

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Feb 3, 2026, 6:57 AM EST - 25 days ago

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Pfizer beats fourth-quarter profit estimates on strong drug demand

Feb 3, 2026, 6:50 AM EST - 25 days ago

Pfizer beats fourth-quarter profit estimates on strong drug demand

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3, 2026, 6:45 AM EST - 25 days ago

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Feb 3, 2026, 6:45 AM EST - 25 days ago

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Feb 3, 2026, 6:40 AM EST - 25 days ago

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Feb 2, 2026, 8:42 AM EST - 26 days ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

SNY

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Feb 2, 2026, 1:01 AM EST - 26 days ago

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

Jan 31, 2026, 3:47 AM EST - 4 weeks ago

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

BBY CAG EQR FRT KEY LYB MAA

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 10:31 AM EST - 4 weeks ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 4 weeks ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 4 weeks ago

Pfizer: A High-Yield Pharma At A Turning Point

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 4 weeks ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 4 weeks ago

Pfizer vs. Merck Stock And JNJ

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Jan 27, 2026, 6:02 AM EST - 4 weeks ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Fliptax
Fliptax Feb. 28 at 3:51 PM
$PFE lets get back to $60+
0 · Reply
Fliptax
Fliptax Feb. 28 at 3:51 PM
$PFE
0 · Reply
TradyMcGradyy
TradyMcGradyy Feb. 28 at 10:36 AM
$BNTX $MRNA $NVAX $PFE
0 · Reply
RolandBless
RolandBless Feb. 28 at 10:10 AM
$PFE pharmaceutical portfolio stability in focus
0 · Reply
SatoshiTrades
SatoshiTrades Feb. 27 at 11:39 PM
$ENSC in PLAY. Ensysce launches formal strategic review — partnerships, licensing, or full buyout on the table. Abuse-deterrent TAAP™ + MPAR® = prime Big Pharma target. $PFE makes strategic sense. Small cap. M&A catalyst. Massive upside potential.
1 · Reply
JBS_84
JBS_84 Feb. 27 at 11:20 PM
$PFE Brilliant let's buy calls that are already expired.
1 · Reply
DragonAlgo
DragonAlgo Feb. 27 at 10:02 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-02-27 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.62 Stop: $0.45 TP1: $0.81 TP2: $1.05 TP3: $1.49 🔗 https://dragonalgo.com
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 27 at 8:50 PM
$PFE wtf is this last hour of trading, it’s literally low volume algo walk up trading
1 · Reply
JBS_84
JBS_84 Feb. 27 at 8:15 PM
$PFE should close in the 27.40s
1 · Reply
SeriouslyWhy
SeriouslyWhy Feb. 27 at 8:06 PM
$PFE your welcome everyone just needed me to leave
2 · Reply
doubleuptwice
doubleuptwice Feb. 27 at 6:53 PM
$PFE looking like Tuesday next week will be fun . I like the way it’s moving
1 · Reply
ReapN
ReapN Feb. 27 at 6:17 PM
$NVAX $PFE $SNY imagine the people that could still be here
0 · Reply
Sb2001
Sb2001 Feb. 27 at 5:38 PM
$PFE seriously, a safe haven? Come on man!!😂
0 · Reply
DisciplinedControl
DisciplinedControl Feb. 27 at 5:08 PM
$PFE pharmaceutical portfolio stability in focus
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 27 at 4:50 PM
$PFE my 27.50 covered calls are lookin spooky
1 · Reply
Pfizer
Pfizer Feb. 27 at 3:47 PM
$PFE Pfizer and Astellas Pharma Inc. today announced positive results from the Phase 3 EV-304 clinical trial for PADCEV (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. These data will be presented today in an oral session and were featured in the press program at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, CA. They will also be discussed with global health authorities for potential regulatory filings. Read more: https://investors.pfizer.com/Investors/News/news-details/2026/PADCEV--Keytruda-Cuts-Risk-of-Recurrence-or-Death-by-Nearly-50-in-Cisplatin-Eligible-Muscle-Invasive-Bladder-Cancer/default.aspx
1 · Reply
DailyAnalysis
DailyAnalysis Feb. 27 at 3:46 PM
$PFE 1D STOCH is bottoming alongside activist investor interest. 1W CCI remains in a long-term basing pattern. 4H RSI shows steady accumulation while 30M signals suggest a low-volatility entry before a 1D breakout attempt on oncology growth. @DailyAnalysis
0 · Reply
Ed_Ng
Ed_Ng Feb. 27 at 3:45 PM
$PFE unbeatable. $60 in 2 years
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Feb. 27 at 3:44 PM
$PFE akshually going up with good news? Thats very Pfizern't
1 · Reply
aba75
aba75 Feb. 27 at 3:42 PM
$PFE Moving at a snail's pace, but at least it's going up!
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 3:00 PM
$PFE Pfizer Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-304 clinical trial for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) in patients with mus…
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Feb. 27 at 12:18 PM
$PFE used to be good news was bad, bad news was worse and couldn't catch a break and not able to show progress. Now it seems defiant to the downgrades ... interesting RBC Capital analyst Trung Huynh initiated coverage on Pfizer Inc (NYSE:PFE) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $27.09 on Wednesday. See how other analysts view this stock.
2 · Reply